Logo image of GBIO

GENERATION BIO CO (GBIO) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:GBIO - US37148K2096 - Common Stock

5.33 USD
+0.03 (+0.57%)
Last: 11/28/2025, 7:34:47 PM
Fundamental Rating

2

GBIO gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 533 industry peers in the Biotechnology industry. The financial health of GBIO is average, but there are quite some concerns on its profitability. GBIO is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year GBIO has reported negative net income.
GBIO had a negative operating cash flow in the past year.
In the past 5 years GBIO always reported negative net income.
In the past 5 years GBIO always reported negative operating cash flow.
GBIO Yearly Net Income VS EBIT VS OCF VS FCFGBIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

GBIO has a Return On Assets (-51.38%) which is in line with its industry peers.
GBIO has a Return On Equity (-123.87%) which is in line with its industry peers.
Industry RankSector Rank
ROA -51.38%
ROE -123.87%
ROIC N/A
ROA(3y)-42.35%
ROA(5y)-35.88%
ROE(3y)-87.81%
ROE(5y)-64.94%
ROIC(3y)N/A
ROIC(5y)N/A
GBIO Yearly ROA, ROE, ROICGBIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for GBIO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GBIO Yearly Profit, Operating, Gross MarginsGBIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -20K -40K -60K -80K

More info and screens

6

2. Health

2.1 Basic Checks

GBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
GBIO has more shares outstanding than it did 1 year ago.
GBIO has more shares outstanding than it did 5 years ago.
There is no outstanding debt for GBIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
GBIO Yearly Shares OutstandingGBIO Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M
GBIO Yearly Total Debt VS Total AssetsGBIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

Based on the Altman-Z score of -9.85, we must say that GBIO is in the distress zone and has some risk of bankruptcy.
GBIO has a worse Altman-Z score (-9.85) than 72.23% of its industry peers.
There is no outstanding debt for GBIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -9.85
ROIC/WACCN/A
WACC8.66%
GBIO Yearly LT Debt VS Equity VS FCFGBIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 4.44 indicates that GBIO has no problem at all paying its short term obligations.
With a Current ratio value of 4.44, GBIO perfoms like the industry average, outperforming 51.22% of the companies in the same industry.
GBIO has a Quick Ratio of 4.44. This indicates that GBIO is financially healthy and has no problem in meeting its short term obligations.
GBIO's Quick ratio of 4.44 is in line compared to the rest of the industry. GBIO outperforms 53.10% of its industry peers.
Industry RankSector Rank
Current Ratio 4.44
Quick Ratio 4.44
GBIO Yearly Current Assets VS Current LiabilitesGBIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for GBIO have decreased strongly by -32.48% in the last year.
The Revenue for GBIO has decreased by -17.82% in the past year. This is quite bad
EPS 1Y (TTM)-32.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%64.35%
Revenue 1Y (TTM)-17.82%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-78.9%

3.2 Future

GBIO is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -3.80% yearly.
Based on estimates for the next years, GBIO will show a very negative growth in Revenue. The Revenue will decrease by -26.69% on average per year.
EPS Next Y-27.52%
EPS Next 2Y26.47%
EPS Next 3Y-6.69%
EPS Next 5Y-3.8%
Revenue Next Year-41.57%
Revenue Next 2Y-46.58%
Revenue Next 3Y-22.85%
Revenue Next 5Y-26.69%

3.3 Evolution

GBIO Yearly Revenue VS EstimatesGBIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
GBIO Yearly EPS VS EstimatesGBIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -10 -20 -30

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GBIO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GBIO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GBIO Price Earnings VS Forward Price EarningsGBIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GBIO Per share dataGBIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 -10 -15

4.3 Compensation for Growth

A cheap valuation may be justified as GBIO's earnings are expected to decrease with -6.69% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.47%
EPS Next 3Y-6.69%

More info and screens

0

5. Dividend

5.1 Amount

GBIO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GENERATION BIO CO

NASDAQ:GBIO (11/28/2025, 7:34:47 PM)

5.33

+0.03 (+0.57%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05 2025-11-05/amc
Earnings (Next)03-11 2026-03-11/amc
Inst Owners62.2%
Inst Owner Change-86.58%
Ins Owners2.86%
Ins Owner Change0.05%
Market Cap35.92M
Revenue(TTM)15.27M
Net Income(TTM)-62.63M
Analysts78.33
Price Target30.94 (480.49%)
Short Float %0.71%
Short Ratio0.64
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)33.67%
Min EPS beat(2)-7.33%
Max EPS beat(2)74.68%
EPS beat(4)2
Avg EPS beat(4)22.43%
Min EPS beat(4)-7.33%
Max EPS beat(4)74.68%
EPS beat(8)3
Avg EPS beat(8)-10.52%
EPS beat(12)6
Avg EPS beat(12)-5.45%
EPS beat(16)8
Avg EPS beat(16)-3.34%
Revenue beat(2)1
Avg Revenue beat(2)30.49%
Min Revenue beat(2)-75.81%
Max Revenue beat(2)136.78%
Revenue beat(4)3
Avg Revenue beat(4)106.66%
Min Revenue beat(4)-75.81%
Max Revenue beat(4)301.43%
Revenue beat(8)7
Avg Revenue beat(8)145.01%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)13.4%
PT rev (3m)13.4%
EPS NQ rev (1m)-61.75%
EPS NQ rev (3m)-36.48%
EPS NY rev (1m)0%
EPS NY rev (3m)-5.54%
Revenue NQ rev (1m)-34.34%
Revenue NQ rev (3m)-72.5%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-12.7%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.35
P/FCF N/A
P/OCF N/A
P/B 0.71
P/tB 0.71
EV/EBITDA N/A
EPS(TTM)-9.34
EYN/A
EPS(NY)-3.89
Fwd EYN/A
FCF(TTM)-17.02
FCFYN/A
OCF(TTM)-16.86
OCFYN/A
SpS2.27
BVpS7.5
TBVpS7.5
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -51.38%
ROE -123.87%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-42.35%
ROA(5y)-35.88%
ROE(3y)-87.81%
ROE(5y)-64.94%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.13
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 22.33%
Cap/Sales 7.09%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.44
Quick Ratio 4.44
Altman-Z -9.85
F-Score4
WACC8.66%
ROIC/WACCN/A
Cap/Depr(3y)120.26%
Cap/Depr(5y)130.66%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-32.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%64.35%
EPS Next Y-27.52%
EPS Next 2Y26.47%
EPS Next 3Y-6.69%
EPS Next 5Y-3.8%
Revenue 1Y (TTM)-17.82%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-78.9%
Revenue Next Year-41.57%
Revenue Next 2Y-46.58%
Revenue Next 3Y-22.85%
Revenue Next 5Y-26.69%
EBIT growth 1Y7.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year36.83%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-111.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-123.86%
OCF growth 3YN/A
OCF growth 5YN/A

GENERATION BIO CO / GBIO FAQ

Can you provide the ChartMill fundamental rating for GENERATION BIO CO?

ChartMill assigns a fundamental rating of 2 / 10 to GBIO.


What is the valuation status for GBIO stock?

ChartMill assigns a valuation rating of 0 / 10 to GENERATION BIO CO (GBIO). This can be considered as Overvalued.


Can you provide the profitability details for GENERATION BIO CO?

GENERATION BIO CO (GBIO) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for GBIO stock?

The Earnings per Share (EPS) of GENERATION BIO CO (GBIO) is expected to decline by -27.52% in the next year.